220 related articles for article (PubMed ID: 31066619)
21. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes.
Choi KM; Jang M; Kim JH; Ahn HJ
Biomaterials; 2014 Aug; 35(25):7121-32. PubMed ID: 24854094
[TBL] [Abstract][Full Text] [Related]
22. Effect of EphA7 Silencing on Proliferation, Invasion and Apoptosis in Human Laryngeal Cancer Cell Lines Hep-2 and AMC-HN-8.
Xiang C; Lv Y; Wei Y; Wei J; Miao S; Mao X; Gu X; Song K; Jia S
Cell Physiol Biochem; 2015; 36(2):435-45. PubMed ID: 25968442
[TBL] [Abstract][Full Text] [Related]
23. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
24. Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing.
Tan YF; Mundargi RC; Chen MH; Lessig J; Neu B; Venkatraman SS; Wong TT
Small; 2014 May; 10(9):1790-8. PubMed ID: 24510544
[TBL] [Abstract][Full Text] [Related]
25. Efficient nanocarriers of siRNA therapeutics for cancer treatment.
Subhan MA; Torchilin VP
Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717
[TBL] [Abstract][Full Text] [Related]
26. Efficiency of resveratrol-loaded sericin nanoparticles: Promising bionanocarriers for drug delivery.
Suktham K; Koobkokkruad T; Wutikhun T; Surassmo S
Int J Pharm; 2018 Feb; 537(1-2):48-56. PubMed ID: 29229512
[TBL] [Abstract][Full Text] [Related]
27. Enhanced delivery of monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly l-lysine nanoparticles loading platelet-derived growth factor BB small interfering RNA by ultrasound and/or microbubbles to rat retinal pigment epithelium cells.
Du J; Shi QS; Sun Y; Liu PF; Zhu MJ; Du LF; Duan YR
J Gene Med; 2011 Jun; 13(6):312-23. PubMed ID: 21674734
[TBL] [Abstract][Full Text] [Related]
28. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
[TBL] [Abstract][Full Text] [Related]
29. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
30. Effects of siRNA specific to the protein kinase CK2α on apoptosis of laryngeal carcinoma cells.
Wang JT; Gong SS
Chin Med J (Engl); 2012 May; 125(9):1581-5. PubMed ID: 22800825
[TBL] [Abstract][Full Text] [Related]
31. Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice.
Yhee JY; Lee SJ; Lee S; Song S; Min HS; Kang SW; Son S; Jeong SY; Kwon IC; Kim SH; Kim K
Bioconjug Chem; 2013 Nov; 24(11):1850-60. PubMed ID: 24107100
[TBL] [Abstract][Full Text] [Related]
32. Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo.
Choi KM; Kim K; Kwon IC; Kim IS; Ahn HJ
Mol Pharm; 2013 Jan; 10(1):18-25. PubMed ID: 22663765
[TBL] [Abstract][Full Text] [Related]
33. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
[TBL] [Abstract][Full Text] [Related]
34. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
[TBL] [Abstract][Full Text] [Related]
35. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
[TBL] [Abstract][Full Text] [Related]
36. Multifunctional Nanodelivery Platform for Maximizing Nucleic Acids Combination Therapy.
Lee SK; Law B; Tung CH
Methods Mol Biol; 2020; 2115():79-90. PubMed ID: 32006395
[TBL] [Abstract][Full Text] [Related]
37. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.
Sarett SM; Werfel TA; Lee L; Jackson MA; Kilchrist KV; Brantley-Sieders D; Duvall CL
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6490-E6497. PubMed ID: 28739942
[TBL] [Abstract][Full Text] [Related]
38. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
[TBL] [Abstract][Full Text] [Related]
39. Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness.
Kim CJ; Terado T; Tambe Y; Mukaisho KI; Sugihara H; Kawauchi A; Inoue H
Int J Oncol; 2018 Jan; 52(1):231-240. PubMed ID: 29115414
[TBL] [Abstract][Full Text] [Related]
40. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
